Tags

Type your tag names separated by a space and hit enter

Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes.
J Am Geriatr Soc. 2009 Jul; 57(7):1238-44.JA

Abstract

OBJECTIVES

To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes.

DESIGN

Cross-sectional survey of medical claims data.

SETTING

Indiana Medicaid claims for 2004.

PARTICIPANTS

Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors.

MEASUREMENTS

Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined.

RESULTS

A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use.

CONCLUSION

Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.

Authors+Show Affiliations

Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, Indiana 47907, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19467148

Citation

Modi, Ankita, et al. "Concomitant Use of Anticholinergics With Acetylcholinesterase Inhibitors in Medicaid Recipients With Dementia and Residing in Nursing Homes." Journal of the American Geriatrics Society, vol. 57, no. 7, 2009, pp. 1238-44.
Modi A, Weiner M, Craig BA, et al. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc. 2009;57(7):1238-44.
Modi, A., Weiner, M., Craig, B. A., Sands, L. P., Rosenman, M. B., & Thomas, J. (2009). Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. Journal of the American Geriatrics Society, 57(7), 1238-44. https://doi.org/10.1111/j.1532-5415.2009.02258.x
Modi A, et al. Concomitant Use of Anticholinergics With Acetylcholinesterase Inhibitors in Medicaid Recipients With Dementia and Residing in Nursing Homes. J Am Geriatr Soc. 2009;57(7):1238-44. PubMed PMID: 19467148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. AU - Modi,Ankita, AU - Weiner,Michael, AU - Craig,Bruce A, AU - Sands,Laura P, AU - Rosenman,Marc B, AU - Thomas,Joseph,3rd Y1 - 2009/04/17/ PY - 2009/5/27/entrez PY - 2009/5/27/pubmed PY - 2009/8/6/medline SP - 1238 EP - 44 JF - Journal of the American Geriatrics Society JO - J Am Geriatr Soc VL - 57 IS - 7 N2 - OBJECTIVES: To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes. DESIGN: Cross-sectional survey of medical claims data. SETTING: Indiana Medicaid claims for 2004. PARTICIPANTS: Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors. MEASUREMENTS: Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined. RESULTS: A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use. CONCLUSION: Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population. SN - 1532-5415 UR - https://www.unboundmedicine.com/medline/citation/19467148/Concomitant_use_of_anticholinergics_with_acetylcholinesterase_inhibitors_in_Medicaid_recipients_with_dementia_and_residing_in_nursing_homes_ L2 - https://doi.org/10.1111/j.1532-5415.2009.02258.x DB - PRIME DP - Unbound Medicine ER -